Compensation for research injuries: Thoughts from a human research ethics committee chair by Cleaton-Jones, Peter
The Venter case for research injury compensation 
following a clinical trial[1] is the first I am aware 
of in South African (SA) courts during my service 
on research ethics committees (RECs) since 1974. 
Moreover, of the several thousand clinical trials 
approved in the past 40 years by the Human Research Ethics 
Committee (Medical) at the University of the Witwatersrand, there 
has been only one claim for compensation for a research injury of an 
enduring nature. In this case, about a decade ago, a participant in a 
clinical trial developed idiopathic hypertension; the sponsor agreed 
that this was trial related, and has provided long-term care for the 
hypertension without a need to approach the courts.
With this limited knowledge I did an online search for court 
cases for compensation due to research injury, particularly 
during clinical trials under the Association of the British 
Pharmaceutical Industry (ABPI) guidelines.[2] My search was 
disappointing because the outcome was swamped with claims 
associated with medical ‘negligence’; linkage to clinical trials and 
the ABPI guidelines was hidden, if present at all. However, one 
case in the UK involving the ABPI guidelines (Wyle vs Grosset 
Greater Glasgow Health Board 2011 CSOH 89) was mentioned in 
the Venter judgement. This limited compensation to ‘appropriate 
medical treatment’.[3]
Section 10 of the Declaration of Helsinki 2013[4] states that 
‘Appropriate compensation and treatment for subjects who are 
harmed as a result of participating in research must be ensured.’ 
Under this principle, what types of compensation are available 
in different countries? I found so much variation between and 
within countries that it would be impossible to discuss this in an 
editorial, or even a full article. However, a recent report from the 
US Presidential Commission for the Study of Bioethical Issues,[5] 
which has two summary appendices listing compensation methods 
in four US federal agencies and 45 ‘international and transnational 
requirements’, is useful.
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A US federal agency that supports much research in SA is the 
National Institutes of Health (NIH). For in-house research, ‘the 
Clinical Centre of the NIH will provide short-term medical care … 
In general, no long-term medical care or financial compensation 
for research-related injuries will be provided …’[5] Those serving 
on RECs in SA will be familiar with the absence of research injury 
compensation in NIH-sponsored research, something challenged 
by SA REC chairs in 2006.[6] In fact, little has changed since 20 years 
ago, when it was reported that in the USA ‘there is no comprehensive 
program to cover injuries resulting from privately and publically 
funded research’.[7]
Is alteration in research injury compensation policy also slow in 
the USA outside the federal system? Resnik et al.[8] looked for change 
in compensation policy over a decade by secondary analysis of data 
sets from surveys in US research institutions in 2002 (N=127) and 
2012 (N=169). There was minimal change in compensation policies, 
the percentage without compensation (including treatment) being 
56.1% in 2000 and 51.2% in 2012. Importantly, Resnik et al.[8] noted 
that a ‘significant percentage of policies contain language that can 
reasonably interpreted as waiving, or appearing to waive, legal 
rights’.
Examination of the summaries of the 45 international 
requirements listed in the Commission’s report[5] shows that 
62% require insurance, 36% want treatment to be provided 
for a research injury, 20% offer economic compensation, 13% 
indemnify researchers and sponsors, 11% have vague statements 
that compensation is needed, and only 1% offer both treatment 
and economic compensation as stated by the Declaration of 
Helsinki.[5] None of the requirement summaries mention quantum 
of compensation, which is not surprising. It is a complex and 
difficult matter, since variables to be considered include who 
should be compensated, for what (will known complications be 
excluded?), by whom, at what quantum, and who will decide. For 
the latter, Denmark, Finland and New Zealand cite general laws 
and government bodies dealing with compensation that would be 
used.[5] Collaboration between legal experts, bioethicists, clinicians 
and insurers will be necessary.
The current Presidential Commission[5] noted that ‘Almost 
all other developed nations have instituted policies to require 
treatment, or compensation for treatment, for injuries suffered 
by research subjects.’ The Commission acknowledged past 
recommendations by presidentially appointed bioethics 
commissions and other groups for the USA to establish federal 
compensation policies, and the lack of progress in fulfilling this. 
In the absence of these policies, local researchers in Africa rely 
on insurance during NIH-sponsored HIV/AIDS clinical trials.[9] 
The current Commission report advised a cautious, systematic 
approach towards establishment of policies.[5] There is no reason 
to believe that change of compensation requirements in SA would 
not follow a similar slow course.
Strode and Singh[1] believe that ‘RECs … protect the rights and 
welfare of research participants by carefully reviewing compen-
sation clauses in informed-consent documents.’ I agree. Since 
change in compensation policy in our country is likely to take 
time to fulfil the requirements of the Declaration of Helsinki,[4] 
what should RECs do now? My view is that potential participants 
need to have a better understanding of the ABPI-based compen-
sation policy.
What happens at present is that late in an information sheet, 
perhaps in the last few of many pages, there is a paragraph or two 
that describes compensation available from the sponsor, under 
certain conditions including the ABPI guidelines, should there be a 
trial-related injury. Included is a statement that ‘this does not affect 
the right of a participant to pursue a legal remedy in respect of 
injury alleged to have been suffered as a result of participation’.[10] 
This is surely similar to the confusing language found in the USA 
by Resnik et al.[8] What some sponsors have been saying in recent 
times seems clearer to me, namely that a participant’s right to claim 
for compensation is not affected, but negligence must be proven.
Whatever information on compensation is provided to a potential 
participant in a clinical trial information sheet, my belief is that it 
should be on a separate page requiring a signature and preferably 
combined with questioning to ensure that the potential participant 
understands it. Perhaps this should be in the front of an informed 
consent form, which would certainly help RECs reviewing an 
application, as well as the potential participant.
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